Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rockwell Medical (RMTI) Gains from Investment Securities (2017 - 2025)

Historic Gains from Investment Securities for Rockwell Medical (RMTI) over the last 13 years, with Q3 2025 value amounting to $124000.0.

  • Rockwell Medical's Gains from Investment Securities fell 1142.86% to $124000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $446000.0, marking a year-over-year increase of 721.15%. This contributed to the annual value of $2.0 million for FY2024, which is 8324.23% up from last year.
  • Rockwell Medical's Gains from Investment Securities amounted to $124000.0 in Q3 2025, which was down 1142.86% from $148000.0 recorded in Q2 2025.
  • Rockwell Medical's Gains from Investment Securities' 5-year high stood at $840000.0 during Q3 2023, with a 5-year trough of $10000.0 in Q2 2022.
  • Its 5-year average for Gains from Investment Securities is $179866.7, with a median of $138000.0 in 2024.
  • Per our database at Business Quant, Rockwell Medical's Gains from Investment Securities surged by 120000.0% in 2023 and then plummeted by 8333.33% in 2024.
  • Over the past 5 years, Rockwell Medical's Gains from Investment Securities (Quarter) stood at $57000.0 in 2021, then surged by 431.58% to $303000.0 in 2022, then soared by 177.23% to $840000.0 in 2023, then tumbled by 96.67% to $28000.0 in 2024, then soared by 342.86% to $124000.0 in 2025.
  • Its Gains from Investment Securities stands at $124000.0 for Q3 2025, versus $148000.0 for Q2 2025 and $146000.0 for Q1 2025.